Tarsus Pharmaceuticals (TARS) Expected to Announce Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS) will likely be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Tarsus Pharmaceuticals to announce earnings of ($1.49) per share and revenue of $186.56 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The company had revenue of $173.91 million for the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. On average, analysts expect Tarsus Pharmaceuticals to post ($4.19) EPS for the current fiscal year and $0.64 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $70.03 on Tuesday. The firm has a market cap of $3.45 billion, a PE ratio of -64.25 and a beta of 0.44. Tarsus Pharmaceuticals has a 12-month low of $53.89 and a 12-month high of $91.53. The company’s 50 day simple moving average is $75.06 and its 200-day simple moving average is $67.98. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, CEO Bobak Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $90.56, for a total transaction of $905,600.00. Following the transaction, the chief executive officer directly owned 827,991 shares in the company, valued at approximately $74,982,864.96. The trade was a 1.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $87.50, for a total transaction of $278,250.00. Following the completion of the sale, the insider directly owned 1,590 shares of the company’s stock, valued at $139,125. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 48,031 shares of company stock worth $4,004,227. Company insiders own 9.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. HC Wainwright reissued a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Finally, Zacks Research upgraded Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $100.86.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.